SYGNIS presents your innovative True Prime technology
the Single Cell Genomics Conference 2015
DGAP-News: SYGNIS AG / Key word (s): Conference SYGNIS presents
Your innovative True Prime Technology on Single Cell
Genomics Conference 2015
09.10.2015 / 13:44
Press Release
SYGNIS presents your innovative True Prime Technology on the
Single Cell Genomics Conference 2015
Madrid, Spain and Heidelberg, August 10, 2015 – SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today
known to their proprietary True Prime Technology
the Single Cell Genomics Conference in 2015, in front of experts from
Universities, companies, associations and government representatives
will present. This year’s conference is organized by
Dutch Hubrecht aligned Institute and will take place from 16th
to 18 September in Utrecht instead.
SYGNIS ‘product portfolio to amplify True Prime
complete genomes from very small amounts of biological samples to
down to single cells, based on a revolutionary new
Multiple Displacement Amplifiations (MDA) technology for the
Multiplication of various DNA and RNA forms for
wide range of applications. Using the
proprietary DNA primase TthPrimPol requires the
True, in contrast to current Prime Technology
Standard technologies no synthetic “primer” (short
DNA molecules, oligonucleotides) to start the reaction.
The properties of the True Prime technology make this
Product very attractive for a wide range of applications and
Analyzes, particularly in life science fields such as of the
Genome analysis of single cells, where researchers biological information
must win from the smallest samples.
Armin Schneider, senior vice president of research at SYGNIS, is
a poster entitled True Prime, a superior technology for
single cell whole genome amplification based on TthPrimPol,
imagine. The poster presentations will be on September 16 from
18:25 until 21:00 clock and on 17 September from 17:10 until 19:30 clock
take place.
The single-cell genomics is rapidly developing into a
important technology for many areas of biological research.
By the versatile application possibilities (sequencing
Single cell genomes, analyzing Einzelzelltranskriptomen,
Different approaches in the field of epigenetic profiling
Single cells), the researchers, the genetic and functional
Properties of individual cells under native conditions
characterize, whereby numerous experimental and
open clinical opportunities.
For more information on the Single Cell Genomics Conference 2015
can be found at:
http://www.weizmann.ac.il/conferences/SCG2015/welcome.
Über True Prime
True Prime is the brand name of a revolutionary, new
Multiple Displacement Amplification and one of the
Key products in SYGNIS ‘portfolio. True Prime is based on
the combination of the company’s DNA primase “TthPrimPol” with
a highly processive and accurate Phi29 polymerase for
uniform amplification of complete genomes for
wide range of applications such as Next Generation Sequencing (NGS)
and the analysis of single cells. The extraordinary ability of
Phi29 polymerase for the separation of DNA duplexes allowed the
direct formation of new primer by TthPrimPol on the straight
exposed strands. These primers serve as attachment points for
Phi29 polymerase, which then directly starts with the amplification, which
an exponential DNA amplification under isothermal conditions
leads without the previously necessary use of synthetic
. Primers
For further information, please contact:
SYGNIS AG MC Services AG
Pilar de la Huerta Raimund Gabriel
CEO / CFO Managing Partner
Tel .: +34 91 192 36 50 210 228 89 30 Tel .: +49
Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, with headquarters in Germany and Spain, specializes in
developing and commercializing innovative products for the
DNA amplification and sequencing. Based on its
proprietary technologies, SYGNIS has a commercial
Developed product portfolio in the key challenges
the rapidly growing fields of molecular biology and the Next
Generation Sequencing addressed. The main products of the company
are on the one hand for the amplification and sequencing
complete genomes developed True Prime product line and
SensiPhi (R) attached to an industry-leading partners
was licensed. Furthermore includes the product portfolio
SunScript reverse transcriptase product family for translation
genetic information from RNA to DNA a. SYGNIS AG is listed in Prime
Standard of Deutsche Börse (Ticker: LIO1; ISIN: DE000A1RFM03)
listed.
### Certain statements contained in this press release in
where there are neither reported financial results nor
other historical information are, are forward-looking nature. It
Such statements are mainly predictions of future results, trends,
Plans or objectives. Such statements are not backed up as absolute
to consider, as they naturally known and unknown risks
and are subject to uncertainties and influenced by other factors
can be, in consequence of which the actual results and the
Plans and goals of SYGNIS materially from those expressed or
can differ implied forward-looking statements. SYGNIS
undertakes no obligation to update these statements publicly
to revise or, whether to reflect new information, future
Events or circumstances or otherwise. ###
09.10.2015 Dissemination of a Corporate News / financial news
transmitted by DGAP – a service of EQS Group AG. For the
Content of this announcement is the issuer / publisher responsible.
DGAP’s Distribution Services include Regulatory Announcements,
Financial / Corporate News and Press Releases.
Media archive at and http://www.dgap-medientreff.de
http://www.dgap.de
Language: German
Company: SYGNIS AG
Waldenhofer Str. 104
69123 Heidelberg
Germany
Phone: 03222 1091 975
Fax: 03222 1096 030
Email: info@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Exchanges: Regulated Market in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
393 705 09/10/2015
ISIN DE000A1RFM03
AXC0113 2015-09-10 / 13: 44
No comments:
Post a Comment